Stephen Rittenhouse

Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.

Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.

Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity.

Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes.

New benzylidenethiazolidinediones as antibacterial agents.

Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues.

Selection of retapamulin, a novel pleuromutilin for topical use.

Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic.

Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.

Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.

A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential.

Challenges of antibacterial discovery revisited.

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.